Janux Therapeutics, Inc.
JANX
$17.11
$1.257.88%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.00M | 439.00K | 9.34M | 10.59M | 13.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.00M | 439.00K | 9.34M | 10.59M | 13.05M |
| Cost of Revenue | 49.92M | 48.24M | 48.24M | 37.25M | 28.69M |
| Gross Profit | -39.92M | -47.80M | -38.90M | -26.66M | -15.64M |
| SG&A Expenses | 39.13M | 46.18M | 43.55M | 41.05M | 39.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 154.29M | 145.32M | 122.92M | 109.44M | 99.01M |
| Operating Income | -144.29M | -144.88M | -113.58M | -98.85M | -85.96M |
| Income Before Tax | -101.90M | -105.64M | -77.74M | -68.99M | -60.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -101.90 | -105.64 | -77.74 | -68.99 | -60.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.90M | -105.64M | -77.74M | -68.99M | -60.54M |
| EBIT | -144.29M | -144.88M | -113.58M | -98.85M | -85.96M |
| EBITDA | -142.22M | -142.80M | -111.54M | -96.79M | -83.88M |
| EPS Basic | -1.68 | -1.80 | -1.36 | -1.28 | -1.18 |
| Normalized Basic EPS | -1.05 | -1.12 | -0.85 | -0.80 | -0.73 |
| EPS Diluted | -1.68 | -1.80 | -1.36 | -1.28 | -1.18 |
| Normalized Diluted EPS | -1.05 | -1.12 | -0.85 | -0.80 | -0.73 |
| Average Basic Shares Outstanding | 242.55M | 235.16M | 227.70M | 214.96M | 204.81M |
| Average Diluted Shares Outstanding | 242.55M | 235.16M | 227.70M | 214.96M | 204.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |